BioLife Solutions (BLFS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.08
- Estimate
- $0.06
- Surprise
- +40.5%
- Revenue (period 2026-06-30)
- $28.5M
- Score today
- 5.3/10
Revenue source: xbrl.
How the report landed
BioLife Solutions (BLFS) beat the $0.06 estimate with diluted EPS of $0.08 — a large 40.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BLFS Sell at 5.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +40.5% surprise compares with a +719.7% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Product: CryoStor products (82.0%)
- Concentration risk — Geographic: United States (80.0%)
- Earnings expected to decline ~67% (cyclical peak)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $36.11
- Price target
- $37.34
- Stop
- $34.19
- Upside to target
- +3.4%
Forward estimates sit below the trailing run-rate (110.3× forward vs 36.4× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
BLFS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $1.78B
- P/E (fwd)
- 110.3
- P/E (ttm)
- 36.4
- 52-week range
- $17.86–$38.10
- Off 52-week high
- 5.2%
- RSI (14)
- 43
- Volume vs avg
- 0.53×
- Score today
- 5.3/10